<div id="readability-page-1">We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. BioMarin Pharmaceuticals Inc. stands second among the most promising stocks. TheFly reported on December 19 that BMRN announced it will acquire Amicus Therapeutics in an all‑cash transaction valued at approximately $4.8 billion, paying $14.50 per share. The deal strengthens BMRN’s […]</div>

拜瑪林制藥

<p>BioMarin 製藥公司以 48 億美元的全現金交易收購 Amicus Therapeutics，每股支付 14.50 美元。這項收購預計將增強 BioMarin 在基因編輯領域的地位，因為分析師將其評為最具前景的基因編輯股票中的第二位</p>

在收購 Amicus 之後，分析師對拜瑪林製藥公司（BMRN）的看法更加樂觀